Adoptive immunotherapy

Research output: Chapter in Book/Report/Conference proceedingChapter


Adoptive immunotherapy typically refers to a cellular infusion product. For these cell therapies, the donor may be autologous or allogeneic, and the product may be minimally manipulated e.g. donor lymphocyte infusion, or the result of a complex isolation and expansion culture e.g. regulatory T cells. This chapter addresses the four main cellular therapies in adoptive immunotherapy, including T cells, dendritic cells (DCs), natural killer (NK) cells, and mesenchymal stem or stromal cells (MSCs), and their clinical applications. Basic research has suggested several possible mechanisms of action, including the ability of MSCs to home to injured tissue and to secrete bioactive molecules to stimulate recovery/repair and inhibit additional inflammation. Standardization is a goal of preclinical development and clinical manufacturing for any trial. Advances in technology have further enhanced one’s ability to bring the next generation of cellular immunotherapies into the clinic.

Original languageEnglish (US)
Title of host publicationRossi’s Principles of Transfusion Medicine
Number of pages9
ISBN (Electronic)9781119013020
ISBN (Print)9781119012993
StatePublished - Apr 15 2016

Bibliographical note

Publisher Copyright:
© 2016 John Wiley & Sons, Ltd.


  • Adoptive immunotherapy
  • Cellular therapies
  • Dendritic cells
  • Inflammation
  • Mesenchymal stem cells
  • Natural killer cells
  • Stromal cells
  • T-cells


Dive into the research topics of 'Adoptive immunotherapy'. Together they form a unique fingerprint.

Cite this